◆ 会议时间：2026年2月26-28日
◆ 会议地点：丹麦 哥本哈根

◆ 会议简介：

2026年第27届欧洲妇科肿瘤学大会(ESGO2026)将于2026年2月26-28日在丹麦哥本哈根举行，会议由欧洲妇科肿瘤学会(ESGO)主办。欧洲妇科肿瘤学会(ESGO)年会/大会是欧洲规模最大的妇科肿瘤学会议，预计有来自世界各地的2800余名专业人士与会。ESGO大会将是一个独特的教育体验，与会者将从超过70个由世界专家主持的涵盖妇科肿瘤学主要议题的科学会议中受益，会议将使用包括全体会议、最佳口头和海报会议等多种形式。ESGO2022将为与会者提供一个学习和讨论妇科癌症研究、治疗和护理方面的最新医学和科学进展，以及与来自世界各地的专家和同行建立联系的机会。

欧洲妇科肿瘤学会（ESGO）成立于1983年，是欧洲领先的妇科癌症研究组织，由来自欧洲和世界各地的3400多名参与妇科癌症治疗、护理、研究的专业人员组成；ESGO致力于通过预防、卓越宣的护理，高质量的研究和教育，提高欧洲妇科（生殖器官和乳腺）癌症患者的健康和福祉。ESGO的愿景是：为欧洲所有妇科癌症患者提供最佳的预防和护理（未经许可禁止复制摘录转载本站任何内容-领域国际医学会议网(lingyuint.com)

ESGO 2026 - 27th European Congress on Gynaecological Oncology
27th Congress of the European Society of Gynaecological Oncology

Date:
February 26-28, 2026

Location:
Copenhagen, Denmark

Organized by:
European Society of Gynaecological Oncology (ESGO)

摘要征文投稿：

Abstracts Topics

• Cervical cancer
• Diagnostics
• Endometrial cancer
• Fertility/Pregnancy
• Miscellaneous
• Ovarian cancer
• Palliative care
• Pathology
• Prevention of gynaecological cancer
• Quality of life after treatment
• Rare Tumours
• Translational research/biomarkers
• Trophoblastic diseases
• Vaginal and vulvar cancer
• Organization of gynaecological cancer care
• Trial in progress
• Patient advocates topic

The Scientific Programme Committee, invited faculty members, and other experts will review the abstracts after the submission deadline in blind review. To keep transparency, please DO NOT refer to institution or hospital where the research took place in the body of the text.

We kindly ask you NOT to submit abstracts on following topics:

• Breast cancer
• Non-oncology related abstracts
• No single case reports unless accompanied by translational research or other wider research relating to the case

Instructions for Abstract Authors

• Abstracts can only be submitted via the online form, abstracts submitted by fax or email will not be accepted.
• Abstracts must be submitted in English, using UK English spelling.
• The presenting author of an accepted abstract must register and attend the congress.
• The number of submissions is limited to 3 per presenting author.
• The number of authors is limited to 20 per abstract.
• Provide a short specific title indicating the scientific content of the abstract.

The background and goals of the study should appear clearly to the reader. The methods need to outline patient group, methods applied, statistical considerations, if applicable. Results must contain data (except for Late Breaking abstracts [LBA]- see below), and the conclusion should be clearly expressed. The following structure will be required:

• Introduction/Background*
• Methodology
• Results*
• Conclusion*
• Disclosures* (online recording via the submission form)

• The title may not exceed 30 words. PLEASE DO NOT USE CAPITAL LETTERS. The abstract text may not be longer than 300 words (excluding title, authors and disclosures).
• All abbreviations must be defined the first time they appear in the text (but do not define in the title).
• Tables, charts and other graphics (for all in total maximum 1) are permitted and must be in high resolution JPG format.

• Authors should indicate their presentation type preference:
  • Oral presentation preferred
  • Paper poster presentation
  • E-poster only
  • Video presentation
  • Oral presentation in the Young investigator session (only for authors up to 40 years)
  • Place holder for LBA

• The Programme committee reserves the right to decide on the final allocation and presentation method.
• Disclosure of potential conflict of interest (e.g., grant support, consultancy, membership on advisory councils, speaker’s bureau) by all authors and source of funding are mandatory. The submitting author is responsible for collecting a Conflict of interest form for all co-authors. All disclosures should be listed within the last 3 years. A COI template is available: ESGO congress COI form.
• Video presentation (abstract): Please note the abstract shall be accompanied with the video file. The file should be in .mp4 format with max. size of 500MB and maximum 5 minutes long.
• Abstracts submitted via commercial entities will be considered. However, these abstracts should report results from collaborative research conducted by independent (non-commercial) investigators. Investigators, as contributing authors who are employees of commercial entities will only be accepted if independent (academic, clinical and/or scientific) investigators are included as authors. The presenting author should not be an employee of the company.
• Systematic review/meta-analysis abstracts are acceptable.
• Trials in progress (TiP) can be accepted as posters/e-posters but will not be accepted as oral presentations. These should not previously have been presented as TiP at an ESGO congress. TiP abstracts have a separate category/topic. It is expected that abstracts submitted as TiP are ongoing trials that have not reached any protocol-specified endpoints for analysis.
• Encore abstracts (from key data presented at 2025 international meeting as an oral presentation) can be accepted only if they have not been published; with modification and new data, if possible.  In case of a conflict of interest, please do not hesitate to contact us for clarification.
• If several abstracts are based on similar analyses of the same database and one of them is selected for oral presentation, the authors might be asked to combine some/all data into one presentation.
• Case reports for single cases will not be accepted unless they contain substantial translational work.
• Late Breaking Abstracts (LBA) are generally reserved for newly emerging data that is not available at the time of abstract submission. These could be for initial presentation of results, or significant secondary endpoint analyses. A placeholder LBA must be submitted containing the preliminary title, background, methods and type of results that will be presented. LBA will generally not be accepted at a later date unless a shell abstract has been submitted.

Once accepted for presentation, following information is applicable:

• Posters and/or ePosters can inlude QR codes with further information, narration or video.
• The copyright of all data belongs to authors who give permission to ESGO for publication in the IJGC and on eAcademy for registered users.
• The embargo for all abstracts end 10 days prior to the congress and on the first congress day in the case of LBA.
• The embargo for data presented orally ends at the start of the session where the data is presented.

注册费：

◆ 参会对象：医生、医院科室主任/副主任、住院医师、医院管理者、医护人员以及从事该领域研究的科学家、研究人员、医药企业代表等等。